Plain-English translation of NCT07001592 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called vvDD-hIL2-2-RG-1, which is a specially engineered virus designed to activate your immune system against cancer. The virus is injected directly into a tumor rather than given through your bloodstream, with the goal of triggering your body's immune cells to attack cancer cells while causing fewer side effects. This treatment is being studied in patients with advanced cancers of the stomach, esophagus, colon, liver, or peritoneum (abdominal lining) that have already stopped responding to standard chemotherapy or immunotherapy.
Most patients with advanced gastrointestinal cancers eventually develop resistance to standard treatments. This medication is being tested because directly delivering an immune-activating virus into the tumor itself might be a more effective way to fight cancer while sparing the rest of the body from severe side effects.
You likely qualify if…
You likely don't qualify if…
You will come to the hospital or clinic to receive a single injection of the medication directly into your tumor under medical supervision. After the injection, you will be closely monitored for at least 28 days to watch for any side effects; the research team will check in with you regularly during this time. The trial involves blood tests, physical exams, and imaging scans to track how the treatment affects your tumor and to ensure your safety.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United States